Measuring the impact of ambulatory red blood cell transfusion on home functional status: study protocol for a pilot randomized controlled trial by Dennis H. Murphree et al.
STUDY PROTOCOL Open Access
Measuring the impact of ambulatory red
blood cell transfusion on home functional
status: study protocol for a pilot
randomized controlled trial
Dennis H. Murphree1*, Theresa N. Kinard6, Nandita Khera5, Curtis B. Storlie1, Che Ngufor1, Sudhindra Upadhyaya1,
Jyotishman Pathak4, Emma Fortune1, Eapen K. Jacob7, Rickey E. Carter1, Karl A. Poterack3 and Daryl J. Kor2
Abstract
Background: Red blood cell (RBC) transfusion is frequently employed in both ambulatory and hospital environments
with the aim of improving patient functional status. In the ambulatory setting, this practice is particularly common in
patients with malignancy due to anemia associated with their cancer therapy. Increasingly, the efficacy of this US$10.5
billion per year practice has been called into question. While it is often standard of care for patients with chemotherapy-
induced anemia to receive ambulatory RBC transfusions, it is unclear to what extent such transfusions affect home
functional status. It is also unclear whether or not changes in functional status in this population can be objectively
quantified using wearable activity monitors. We propose to directly measure the impact of outpatient RBC transfusions
on at-home functional status by recording several physiological parameters and quantifiable physical activity metrics,
e.g., daily energy expenditure and daily total step count, using the ActiGraph wGT3X-BT. This device is an
accelerometer-based wearable activity monitor similar in size to a small watch and is worn at the waist. Study
participants will wear the device during the course of their daily activities giving us quantifiable insight into
activity levels in the home environment.
Methods/design: This will be a randomized crossover pilot clinical trial with a participant study duration of
28 days. The crossover nature allows each patient to serve as their own control. Briefly, patients presenting at a
tertiary medical center’s Ambulatory Infusion Center (AIC) will be randomized to either: (1) receive an RBC
transfusion as scheduled (transfusion) or (2) abstain from the scheduled transfusion (no transfusion). After an
appropriate washout period, participants will crossover from the transfusion arm to the no-transfusion arm or
vice versa. Activity levels will be recorded continuously throughout the study using an accelerometry monitor.
In addition to device data, functional status and health outcomes will be collected via a weekly telephone
interview. The primary outcome measure will be daily energy expenditure. Performance metrics, such as step
count changes, will also be evaluated. Additional secondary outcome measures will include daily sedentary time
and Patient-reported Outcomes Measurement Information System (PROMIS) Global 10 Survey scores.
Discussion: This trial will provide important information on the feasibility and utility of using accelerometry
monitors to directly assess the impact of RBC transfusion on patients’ functional status. The results of the study
will inform the merit and methods of a more definitive future trial evaluating the impact of ambulatory RBC
transfusions in the target population.
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Background
The number of red blood cell (RBC) units transfused an-
nually approaches 14 million in the United States (US)
alone [1]. With an estimated cost of US$761 per RBC
unit [2], this equates to US$10.5 billion in annual health
care expenditures. Notably, the efficacy of RBC transfu-
sion has been increasingly called into question [3]. This
fact, when considered in concert with the underappreci-
ated costs and risks of RBC transfusion, has resulted in a
progressive move towards more conservative RBC trans-
fusion practices [4].
Importantly, the evidence underlying these trends has
primarily focused on the provision of RBC transfusion in
the hospital environment. In contrast, very little data are
available to guide transfusion practices in the outpatient
ambulatory setting. This represents a key knowledge gap
in current transfusion practice, and addressing this gap
is an important goal of the proposed study.
In the ambulatory environment, RBC transfusions are
frequently administered with the intention of improving
patients’ functional status. Indeed, survey responses sug-
gest that a patient’s functional status is the second leading
indication for RBC transfusion trailing only the pretrans-
fusion hemoglobin (Hgb) value [5]. However, data sup-
porting this practice are extremely limited. A secondary
outcome of the well-publicized Transfusion Trigger Trial
for Functional Outcomes in Cardiovascular Patients
Undergoing Surgical Hip Fracture Repair (FOCUS) specif-
ically evaluated the impact of RBC transfusion practices
on gross measures of patient’s functional status [6]. In this
large clinical trial, more liberal RBC transfusion practices
were not associated with improved functional status.
Additional investigations have also failed to identify an
association between the presence of anemia and quality
of life (QoL) measures [7].
In contrast, a limited number of investigations do in
fact support improved functional status with more liberal
RBC transfusion practices [3, 8]. These investigations typ-
ically evaluate patient functional status in the health care
environment (e.g., Timed Up and Go Test in the health
care provider’s office [9]) or via survey responses to ques-
tionnaires such as the Medical Outcomes Study 36-Item
Short-Form Health Survey (SF-36) [8].
Importantly, no well-designed trials have evaluated the
impact of RBC transfusion on functional status in the
patient’s home environment, arguably a far more rele-
vant outcome to potential transfusion recipients. Indeed,
the efficacy of RBC transfusion in the ambulatory setting
remains very much a matter of debate. To this point, on-
going equipoise in this area was recently highlighted at
the 2015 National Heart, Lung, and Blood Institute State
of the Science Meeting in Transfusion Medicine where
the identification of new strategies or technologies that
may help to clarify the role of RBC transfusion in the
ambulatory setting was noted to be a topic of significant
interest.
Beyond unclear efficacy in the ambulatory setting, it is
also important to recognize that every transfusion epi-
sode carries the potential for meaningful risk. As exam-
ples, transfusion-related acute lung injury (TRALI) and
transfusion-associated circulatory overload (TACO) are
respiratory complications resulting from transfusion
and are the leading causes of transfusion-related death
in the US [10]. Although great strides have recently
been made in predicting patient-specific risk prior to
transfusion [11–13], the risk remains serious. Furthermore,
despite their significance, patients and their clinical teams
frequently fail to recognize these transfusion-related re-
spiratory complications [14–16]. Compounding the risk
landscape is the consideration that at present there are es-
sentially no data evaluating the risks of transfusion in the
ambulatory setting.
The introduction of innovative mobile health (mHealth)
technologies creates unique opportunities to study pa-
tients’ functional status in a more robust manner and in
the setting that matters most: their home. Indeed, as the
accuracy of these novel devices improves, their potential
application to studying outcomes in the home environ-
ment moves closer and closer to a reality.
Aims and objectives
Primary
In light of the ongoing equipoise regarding the efficacy
of RBC transfusion in the ambulatory setting, the known
risks associated with blood product administration, and
the availability of innovative technologies that are able
help to address these concerns, the primary aims of our
proposed protocol are as follows:
Specific aim 1: to evaluate the impact of RBC
transfusion on home functional status as assessed by
physical activity metrics recorded by a wearable
ActiGraph wGT3X-BT mHealth device. We hypothesize
that the percent change in mean daily physical activity in
the 7 days following randomization will be greater during
the study periods where participants received an RBC
transfusion than during the periods where an RBC
transfusion was not received.
Specific aim 2: to evaluate the correlation between
physical activity as assessed by the accelerometer and
subjective functional status as assessed with the
Patient-reported Outcomes Measurement Information
System (PROMIS) Global 10 Survey. We hypothesize
that there will be a direct correlation between physical
activity as assessed by the device and the subjective
functional status as assessed by the PROMIS Global 10
Survey.
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Secondary
As a pilot trial we further delineate a set of secondary
objectives. These are less formal than our primary objec-
tives and are designed to gauge study feasibility, with a
particular focus on scalability of methods to a potentially
larger future trial. To that end we aim to evaluate the
suitability of the ActiGraph wGT3X-BT for use in our
target population. While the device has been validated in
terms of its technical measurement [17–22], it remains
an open question as to whether or not our patient popu-
lation, most of whom are receiving chemotherapy or are
transplant recipients, will display a level of adherence
that is sufficient for answering our larger clinical question.
We will also monitor enrollment volume, trial completion
volume, device failure rates, and other such measures
which might be of practical importance when considering
scaling to a larger future trial.
In order to consider whether or not to move forward
from a pilot trial to a larger future randomized clinical
trial, we will carefully evaluate the results for a signal of
efficacy. If there is strong evidence that RBC transfusion
is efficacious in improving patient activity levels a larger
trial is less likely to be considered. Alternatively, if there
is evidence that “no transfusion” is better, or if the results
are equivocal, we are more likely to pursue a larger trial.
In addition to intervention efficacy, we will also assess
both the feasibility of scaling the trial to a more definitive
phase II/III design and the impact of any adverse events.
We will carefully consider participant adherence rate and
the potential for increasing enrollment as prerequisites for
proceeding to a larger trial. Adverse events, if any, will be
evaluated as outlined by the Safety and Monitoring Plan
(Additional file 1). The final document reporting the
results of this trial will follow the main Consolidated Stan-
dards of Reporting Trials (CONSORT) 2010 Statement:
extension to randomized pilot and feasibility trials [23].
Both this trial and any future trial will follow the Standard
Protocol Items: Recommendations for Interventional
Trials (SPIRIT) Checklist (Additional file 2).
Methods/design
Study design
This will be a randomized, two-group, crossover, pilot
clinical trial (Fig. 1). Following this design each subject
serves as their own control. Randomization is to help
eliminate bias due to any time-dependent change in sub-
ject health or chronological effects that may result from
a nontransfusion period.
Participants and screening
Study participants will be identified in the Ambulatory
Infusion Center (AIC) of a tertiary care medical center.
The study population will consist of adult (aged 18 years
or older) male and female hematology and oncology
patients presenting to the AIC with anemia (Hgb under
practice standard threshold for transfusion, e.g., 7.0–9.0 g/
dL) and who are planned to undergo routine RBC transfu-
sion. Subjects with at least one prior presentation to the
AIC within 3 months of the screening visit will be eligible
for study participation. This inclusion criterion has been
selected due to the fact that our preliminary research indi-
cates that those who present to the AIC on more than one
occasion for RBC transfusion are highly likely to present
for a subsequent RBC transfusion in a 28-day time frame.
A full list of the inclusion and exclusion criteria are
provided in Table 1.
Fig. 1 Study design
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For the exclusion criteria of pregnancy, potential study
participants in the reproductive age group will be asked
if they might be pregnant. If the response is “yes” or
“unknown,” the potential study participant will be ex-
cluded. Screening/consent logs will be maintained cen-
trally to allow generation of a CONSORT diagram, but
will also made available to the transfusion medicine ser-
vice at Mayo Clinic in Phoenix, AZ, USA to facilitate
the procedures outlined below. Consenting participants
will be provided with an accelerometer to wear continu-
ously for the duration of their involvement in the trial
(28 days). This device, described further below, will auto-
matically capture relevant physiological data with no need
for intervention by the patient. Following the trial, partici-
pants return the device by mail and data are retrieved by
the investigative team.
The accelerometer chosen for this study is the ActiGraph
wGT3X-BT (ActiGraph Corp, Pensacola, FL, USA). These
devices are similar in size and weight to a simple wrist-
watch, and are typically worn at the wrist, ankle or waist.
By capturing and interpreting acceleration data the device
objectively measures a patient’s physical activity through
metrics such as step counts, energy expenditure, daily
metabolic equivalent (MET) rates, activity intensity, activity
bouts, and sedentary bouts. For the current study, the de-
vices will be worn at the waist in consideration of the more
extensive peer review given to waist-based algorithms used
to interpret raw accelerometer data. Additional measurable
quantities include wear time, heart rate, RR intervals, and
body position.
All study participants will be contacted weekly via tele-
phone for the duration of the study (expected to be
28 days). The purpose of these communications is to bet-
ter understand wearability, enhance protocol compliance,
and assess satisfaction with the device. The Data Capture
Form used by the study coordinator (SC) is available as
supplemental material to this article (Additional file 3). All
comments by participants will be logged by the SC, giving
the team insight into participant interaction with the de-
vice and protocol. Inquiries into life events that may im-
pact home functional status (e.g., injuries, illnesses, other
events) will also be made. Finally, symptoms related to the
intervention of interest (transfusion versus no transfusion)
will also be assessed during each of these correspon-
dences. Specific inquires will include evidence of profound
anemia, renal failure, myocardial infarction, nonhemorrha-
gic stroke, mesenteric ischemia, syncope, falls, shortness of
breath, and chest pain or pressure as well as any medical
encounters including nonstudy transfusion events. All re-
sponses will be augmented with data recorded in partici-
pants’ electronic health records.
Randomization
After informed consent has been obtained, study partici-
pants will be stratified into those that are actively receiv-
ing chemotherapy and those that are not. Within each
stratum, participants will be randomized using simple
randomization (Pr(transfusion group first) = 0.5). Patients
successfully enrolled will be randomized to one of two
transfusion/no transfusion sequences (Fig. 1). The SC will
obtain the randomized sequence from the Research Elec-
tronic and Data Capture (REDCap) randomization mod-
ule. After randomization, the SC will inform the AIC of
the appropriate timing of the no-transfusion study period
so that an updated order set can be prepared. It is rec-
ognized that using simple randomization may result in
imbalances in the transfusion sequences, but simple
randomization was selected for this study for ease of
implementation. The crossover design also helps miti-
gate confounding provided that there is no period effect
observed in the data.
Intervention
Those randomized to transfusion will receive the standard-
of-care-ordered RBC transfusion. This means that they will
receive the transfusion as specifically ordered by their pri-
mary physician, typically one to two units of allogeneic
RBCs. Those randomized to the no-transfusion arm will be
discharged from the AIC without receiving an RBC trans-
fusion. The patients who are randomized into the transfu-
sion group will be crossed over into the no-transfusion
group and the patients who are randomized into the no-
transfusion group will be crossed over into the transfusion
group at a subsequent visit. The time of this crossover for
a given patient will be at their next scheduled transfusion
that is no less than 1 week from the time of their most re-
cent RBC transfusion in this trial.
Blinding
Due to the nature of the intervention (transfusion versus
no transfusion), blinding to the intervention will not be
feasible for either the patient or the clinical team in this
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Age ≥18 years Refusal to provide informed consent
At least one prior encounter
in the AIC
Refusal by the health care team
Planned RBC transfusion Acute ischemia (e.g., myocardial infarction





believed related to anemia)
Nonambulatory functional status
Established or uncertain pregnancy status
AIC Ambulatory Infusion Center, RBC red blood cell
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pilot clinical trial. The accelerometer does not provide
any visual indication of activity levels (e.g., no step count
or estimated energy expenditures), so participants will
be blinded to the data accumulated by the device. With
the exception of the Data Monitoring Committee, inves-
tigators will not have access to the accelerometer data
until the completion of the trial. Patients may access
their data after completion of the trial by request to the
study team. Because blinding to the intervention is im-
possible, and because the purpose of the trial is carefully
explained to participants beforehand, we note the poten-
tial for both performance and detection biases. In par-
ticular, many participants may have an expectation of
lower functional status after a no-transfusion encounter.
One downstream consequence of this is a potential bias
towards lack of effect, meaning that transfusions may be
biased to appear more effective than the no-transfusion
intervention. Concerns related to selection bias are ex-
pected to be largely mitigated by randomization and by
the crossover nature of the design. Nonetheless, risks re-
lated to residual biases resulting from unique character-
istics associated with patients who consent to participate
in this trial clearly remain.
Measures
The primary outcome measure of this study is the
estimated daily energy expenditure using, e.g., the
Williams Work-Energy Approximation calculated from
acceleration-based activity counts and body weight. We
choose this metric because it has been shown to be corre-
lated with energy expenditure estimations from indirect
calorimetry, is a clear indicator of activity level and has
been well studied in the medical literature [17, 19–22, 24].
We emphasize that our study design seeks to measure
changes in activity levels, thus the absolute accuracy of
the energy expended by a participant is not critical to our
broader clinical question. Secondary outcome measures
include daily step count, daily sedentary time, MET rate,
and PROMIS Global 10 Survey results. This survey is a
ten-question assessment designed to measure overall
physical, mental, and social health as well as pain, fa-
tigue, and perceived QoL. Further exploratory outcome
measures will consider activity bout counts, estimated
energy expenditure on a more finely resolved time scale
(e.g., minute to minute), nonintervention RBC transfu-
sions, and need for hospital admission or other health
care encounters.
Data collection and management
Sources and repositories
There are five sources of data in this trial – base data
collected by the devices, derived data interpreted by the
device analysis software, weekly survey data collected via
telephone, study participation data such as Consent
Forms, and finally, encounter-associated data such as SC
encounter notes or laboratory results measured in the
AIC.
During the enrollment and data collection phases of
the study, the primary data repository will be a set of
hard copy study participant files that will be maintained
by the lead SC at the AIC. A centralized digital data store
(CDS) will also be maintained at an access-restricted and
access-logged study site within Mayo Clinic’s secure
network. As the study progresses and patient data are
recovered from devices, this raw device data will be
added to the CDS. In order to facilitate ease of inter-
pretation and analysis after collection, the CDS will also
be tied to a REDCap store. Only those with approved
access to the REDCap data management system will
have access to the study data. Telephone survey and
AIC encounter data will also be transferred from the
hard copy files into REDCap by the SC.
During the analysis phase, all derived data and global
study result data will also be stored in the CDS. Upon
study data collection completion, all relevant physical
files not yet present in the CDS will be scanned and in-
tegrated into the digital store. Physical files will be held
and then disposed of according to the Mayo Clinic record
retention policy. The primary repository of data for
analysis and reporting will thus be the CDS.
Practice logistics and workflow
A critical component for the successful completion of this
study is close integration with the current hematology and
oncology practices at the AIC. From a practical perspec-
tive, engineering this integration has been the most chal-
lenging aspect of moving the study forward. Because of
this, we detail our practice logistics and workflow model.
It is important to remember that in this protocol not
transfusing the patient is the intervention – otherwise
standard practice is followed. Thus, from a practice lo-
gistics and patient safety point of view it is during the
no-transfusion arm that special care must be taken.
The current practice at the AIC is for patients receiv-
ing transfusion therapies (e.g., chemotherapy) to be asso-
ciated with a set of standing orders by their practicing
physician. These standing orders are typically directions
to transfuse the patient when their Hgb is measured
below a specific level. For many practicing physicians
this Hgb level will be between 7.0 and 9.0 g/dL. These
standing orders are specified for a defined time period
up to 3 months so their modification is an important as-
pect of implementing the proposed protocol.
When a SC identifies a patient who appears to be a
likely candidate, they will contact the potential study
participant’s primary physician to receive conditional
approval for inclusion in the study. Patients receiving
conditional provider approval will have Hgb levels
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monitored on the day of their AIC visit by the SC. If
the Hgb is within the range prescribed for transfusion,
the patient is approached for screening and informed
consent. If enrolled, the SC will randomize the partici-
pant. If the participant’s next encounter is to transfuse,
no change to the standing orders is required.
If the patient’s next encounter is no-transfusion, new
standing orders are requested. These orders are designed
to avoid RBC transfusion unless specific “over-riding”
RBC transfusion criteria are present. These “over-riding”
RBC transfusion criteria include: acute ischemia (e.g., MI,
CVA), Hgb <7.0 g/dL, active bleeding, and symptomatic
anemia (hypotension, tachycardia, angina or syncope/
presyncope believed related to anemia). If none of the
above mentioned “over-riding” RBC transfusion criteria
are present, the patient will not be transfused.
After the participant crosses from one study arm to the
other, the SC requests new standing orders as necessary.
Data monitoring
For this trial, data monitoring consists of measures re-
quired for patient privacy and to ensure the success of the
trial. Privacy compliance will follow the standards set by
both the Health Insurance Portability and Accountability
Act (HIPAA) and by Mayo Clinic internal standards. To
help ensure the accuracy of the study data, the Data
Monitoring Committee of Drs. Murphree and Kor will
randomly sample and review the validity of data col-
lected, especially device data. Throughout the trial on-
going assessment will monitor for device data loss,
partial study completion, and other potentially unfore-
seen data concerns. In the event of data loss due to par-
tial study completion, the patient will be removed from
the cohort. In the event of data loss due to device issues
or other unforeseen events the impact of the loss will
be assessed by the investigators. If the loss compromises
the integrity of the study the patient will be removed from
the cohort. A valid device wear hour is defined as ≤30 min
of consecutive “zero” values (no activity) and a valid day
as ≥10 wear hours per day [25]. If the loss is consistent
with reasonably acceptable missing data; for example, the
subject forgetting to put the device on for an hour after
bathing, then the missing data will be dealt with via appro-
priate statistical methods. These could include amongst
others a Bayesian-based imputation or an all-available
average, with the appropriate method chosen based on the
nature of the missingness. Care will be taken to insure
consistency across subjects and missing-data episodes.
Statistics
General descriptive statistics and preliminary data screening
Baseline demographics, clinical characteristics, and
procedure-related information will be presented as
median (25–75% interquartile range (IQR)) for continu-
ous data elements and frequencies (%) for categorical
data.
Accelerometer data will be preprocessed by the ActiLife
[26] software to convert the raw accelerometer signal into
expressions of movement and energy expenditure. These
calculations require some basic patient information (e.g.,
weight), so the device configuration will be verified prior
to finalization of the calculations. For the primary analysis,
we will aggregate the summaries on a daily basis. For ex-
ploratory analysis we will use the summaries on a finer
time resolution (e.g., minute to minute) to determine
whether this provides a more sensitive method of detect-
ing subtle changes in activity levels.
Primary analysis
The primary outcome analyses will be performed using
an “as treated” rather than an “intention-to-treat” analysis
set while accounting for the crossover design. This ap-
proach is most appropriate for this pilot clinical trial,
which primarily aims to understand home functional sta-
tus as it relates to ambulatory RBC transfusion. For statis-
tical comparisons, we will fit a random effects model that
utilizes daily total energy expenditure as the dependent
variable and days from transfusion or control visit
(“placebo” visit where no transfusion was performed).
For simplicity, we will include the mean daily measure-
ments for the 3 days prior to the transfusion/control
visit as covariates in the model, and consider the 7 days
after transfusion/control visit in the model. This censoring
of data beyond 7 days after the transfusion/control visit is
to avoid carryover effects with the model. We will test the
transfusion indicator by study day interaction, with adjust-
ment for baseline activity, for the primary hypothesis. This
parameter will quantify how the profile of activity differs
with and without transfusion while accounting for the
variation in activity between participants by means of the
random effect and baseline adjustment. Contrasts will be
constructed to quantify the difference in the change in ac-
tivity between these visits.
Sensitivity analyses will attempt to model the change
in activity levels in the days after transfusion. These ex-
ploratory models will consider a potential initial boost in
activity with linear or exponential trends to account for
the change in activity over the 7 days after transfusion.
These models will also include subject random effect and
account for time-series correlation. These analyses will be
expanded to include all data measured over the 28-day
period.
Secondary endpoint analysis
Secondary endpoints measured by the accelerometer will
be modeled similarly to the primary outcome measure.
The association of the PROMIS Global 10 Survey score
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and activity will be quantified by the rank order correl-
ation of the area under the curve for the incremental
gain in activity over the 7 days (mean of the 7 days after
transfusion/control visit minus the mean of the 3 days
prior to the transfusion/control visit) and the PROMIS
Global 10 Survey total score. We will conduct this on
the entire data (transfusion and control visits) as well as
with a partial correlation controlling for whether a trans-
fusion was actually conducted.
Safety analysis
Adverse events will be captured and summarized. These
events will be attributable to whether or not they were
transfusion-related or related to withholding the transfu-
sion. The Data and Safety Monitoring Plan submitted to
the Mayo Clinic Institutional Review Board (IRB) includes
definitions of adverse events and reporting requirements.
This monitoring plan is also available as supplemental ma-
terial to this article. No formal stopping rules for safety
are proposed, so standard descriptive summaries will be
tabulated.
Exploratory analyses
Predictor variables other than the intervention, including
pertinent baseline demographics and clinical characteris-
tics such as age, sex, race, comorbidities, medications
(including chemotherapy regimens), and pretransfusion
functional status, will be recorded. Additional predictor
variables will include vital signs and laboratory values
that are obtained during the course of routine care. Re-
sponses from the weekly telephone communications will
also be recorded for potential analysis.
Sample size considerations and recruitment
This is a pilot study to determine whether accelerome-
ters are sensitive enough to detect change in functional
status in patients undergoing ambulatory transfusion
services. The primary hypothesis is to detect change in
total energy expenditure after the transfusion in both be-
tween and within individual comparisons. A minimum
clinically relevant difference is not yet known for this
outcome. To estimate the sample size, we approach the
calculation from the perspective of having sufficient data
to estimate the standard deviation so that we could plan
a follow-up study. Julious [27] recommends studying 12
participants per group for such aims. We apply this rec-
ommendation to this study by assuming that we want at
least 12 participants to complete the first randomized
phase of the crossover design (i.e., the parallel group
portion of the study). Based on this, we will want to have
at least 24 subjects who will provide evaluable data from
the activity monitor. We therefore adjust the sample size
upwards by 25% to account for attrition and/or changes
in the transfusion schedule. Thus, our total planned
sample size is 30 participants. Preliminary research with
clinicians familiar with the infusion center patient
population suggests that an enrollment of this size
should be readily achievable. Specific strategies for
achieving adequate enrollment include presentations to
the hematology and oncology practices in order to ad-
vertise the study to providers, as well as access to the
Mayo Clinic patient scheduling and electronic health
record system. This will ensure the ability to have suffi-
cient on-site recruiting staff on days where patients
known to be eligible are scheduled for transfusion.
Discussion
Blood product transfusion is a frequently employed med-
ical practice, with an estimated 5 million patients [28] an-
nually receiving blood in the US alone. However, despite
its relative ubiquity, practitioners are increasingly ques-
tioning the utility of the practice. Concern stems from
three sources – the recognition of risks associated with
RBC transfusion, the uncertain efficacy in improving pa-
tient outcomes, and the expense of this limited resource.
In terms of efficacy in improving patient outcomes,
the landscape is complicated. While it is well documented
that severe anemia increases a patient’s risk of mortality
[29–33], it is often unclear whether correcting the anemia
results in an improved outcome [34, 35]. While there is
growing consensus that blood transfusions save lives for
some of the sickest patients (e.g., those with hemorrhagic
shock), for many patients, a transfusion may cause more
harm than good. Recent work examining the effects of
more restrictive transfusion practices has found significant
improvement in patient outcomes across all hospital envi-
ronments [36], and a large number of studies document
allogeneic transfusion as being associated with a variety of
adverse surgical outcomes as well as adverse clinical out-
comes, particularly for cancer patients [37–45].
There is a striking lack of data regarding transfusion
in ambulatory patient populations. This current work is
particularly relevant because no published studies have
examined an optimal transfusion threshold for ambula-
tory patients. The current state of knowledge regarding
transfusion efficacy has been acquired from studies of
hospitalized patients.
Some work has been done examining the effects of
transfusion on chronically anemic populations, specific-
ally those with myelodysplastic syndromes (MDS) [46].
One small study [47] found that treating patients to a
target Hgb of 12.0 g/dL by either darbepoetin alfa injec-
tion or via RBC transfusion resulted in significant im-
provement in QoL from both treatments. If replicated at
scale, this might perhaps suggest modifying transfusion
practice for this population. More generally, a recent
medical literature review [48] concludes that there is
currently a lack of evidence to support a particular
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transfusion strategy for patients with MDS and calls for
robust randomized trials. There are currently two ongoing
clinical trials seeking an optimal transfusion threshold for
improving QoL in patients with MDS: ClinicalTrials.gov
#NCT02099669 and ISRCTN #26088319. Both are to
complete in 2016 and are examining QoL effects of liberal
versus restrictive transfusion strategies.
Limited work has also been done considering late-
stage cancer patients in a palliative care setting, with
two studies [49, 50] from the late 1990s indicating relief
of several symptoms. In a more recent review [51], the
authors found evidence of relief for fatigue and breath-
lessness, while also noting a significant proportion of
participants dying within 2 weeks of transfusion. These
investigations further highlighted the need for higher-
quality future studies.
The dangers of RBC transfusion can fall into two
categories: immunological and nonimmunological
transfusion reactions. Life-threatening immunological
transfusion reactions include anaphylaxis, acute hemolysis
and TRALI. Nonimmunological transfusion reactions that
contribute to morbidity and mortality include TACO and
transfusion-transmitted infection. Long-term risks of
transfusion to a chronically anemic patient include iron
overload which may result in multiorgan damage. While
some risks have been dramatically reduced, many risks
continue to persist. For example, transfusion transmission
of the well-characterized viruses, such has hepatitis C
virus and human immunodeficiency virus, has been sig-
nificantly reduced by implementing donor screening,
while other potential transfusion-transmitted infections
remain a moving target and require constant vigilance.
The recent emergence of Zika virus in the US and corre-
sponding reactions by the Center for Disease Control and
AABB illustrates this particular challenge.
In addition to the above concerns about efficacy and
safety, it is important to remember that blood products
are a precious resource. Considering data from 2011 [1],
the available supply of whole blood/RBC units exceeded
the number of transfused units by only 5.2%, with a
trend in donation rates dropping 3–4% per year. An
aging US population can only be expected to exacerbate
the situation. Furthermore, the direct and indirect costs
associated with blood product transfusion are rising
[52]. Goodnough et al. [36] found that over a 5-year
period, implementing a best-practice alert triggered for
higher Hgb transfusions saved a large hospital US$1.3
million annually in purchasing costs alone.
With the above in mind, it is clear that deeper under-
standing of the true utility of RBC transfusion is of vital
importance to the field. The randomized crossover clin-
ical trial proposed here aims to provide preliminary in-
formation on the feasibility of measuring the efficacy of
RBC transfusion in improving home functional status
with a wearable activity monitor. The study, while it can
be described as a pilot, is robust in that it utilizes a ran-
domized crossover design, incorporates an objective
measurement of activity based on accelerometer data,
and includes patient-reported health status. This study
will provide novel data that will aid in the elucidation of
transfusion’s influence on ambulatory activity following
outpatient transfusion.
In addition to the strengths of the trial noted above,
we also acknowledge potential weaknesses of the protocol.
Such limitations include concerns relating to the detect-
ability of activity level in what may often be a sedentary
population with variable daily activity levels, risk that the
effect from transfusion may exceed the 1-week washout
period, and difficulty in recruiting patients who will be
willing to consistently wear a monitor for 28 days. Though
we acknowledge these potential challenges, the insights
gleaned will greatly facilitate the potential design and con-
duct of a future, more definitive, clinical trial. We look for-
ward to seeing the results of this trial and to gaining
important insight into this clinically relevant question.
Current study status
Patient recruitment began in August 2016 and is due to
be completed in December 2017.
Additional files
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